

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 14-186159				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
PALABRAS CLAVE UTILIZADAS		CIRCADIAN RHYTHM DISORDERS; TASIMELTEON; MELATONIN AGONIST; MEASURING CIRCADIAN RHYTHM; BLIND PATIENTS.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 31/00. CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
ESPACENET y Patbase	WO2007137244	29/11/2007	No aplica para materia no patentable (MT)	A
	Robert L Sack ET AL	10/12/2000	No aplica para materia no patentable (MT)	A
	OKAWA ET AL	25/10/2007	No aplica para materia no patentable (MT)	A
	UCHIYAMA M ET AL	01/06/2009	No aplica para materia no patentable (MT)	A
	RAJARATNAM S M ET AL	07/02/2009	No aplica para materia no patentable (MT)	A
	HARDELAND RUEDIGER	01/07/2009	No aplica para materia no patentable (MT)	A
	HARDELAND R	01/01/2009	No aplica para materia no patentable (MT)	A
	WALDEMAR OCKERT	20/07/2012	No aplica para materia no patentable (MT)	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
MT= Método de Tratamiento				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	
---	--

Fecha del reporte de búsqueda:	24-10-2018
--------------------------------	------------

PATBASE

PatBase

www.patbase.com/default.asp

80%

Buscar

Más visitados

EPO - Home

Common Citation Do...

www.uspto.gov

Public Pair - Public Pair

Bancolombia Sucursal...

Recibidos - nvelascog...

Banco Finandina - Sol...

Academia de la OMPI

PatBase

Username: SIC11@patbase.com
Subaccount: nelson velasco

Menu - Search - History - Session - Folder - Order - Help - Logoff

Search 1: "TAC=(CIRCADIAN RHYTHM DISORDERS and TASIMELTEON.)" * 1-2 of 2

Display format: Classic Sorted by: Publication date asc Print Save/export Snapshot Visual explorer Analytics

1) Family number: 54419276 (US2013197076A)

Similar - Translate - Full-text - Status - Citations

Title: [EN] TREATMENT OF CIRCADIAN RHYTHM DISORDERS

Abstract: Source: US2013197076A [EN] Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

PatBase - US2013197076_A1
Patent Application Publication Aug 1, 2013 Sheet 1 of 13 US2013197076_A1

ESPAENET

Cited in

International search

[Y]★ [WO2007137244](#) (VANDA PHARMACEUTICALS INC [US], et al) [Y] 1-24 * p. 2, l. 11-13; Example 1; claims 5, 17 *;

[Y] - Robert L Sack ET AL, "ENTRAINMENT OF FREE-RUNNING CIRCADIAN RHYTHMS BY MELATONIN IN BLIND PEOPLE", N Engl J Med 2000;343, (20001210), pages 1070 - 1077, URL: <http://www.nejm.org/doi/pdf/10.1056/NEJM200010123431503>, (20130326), XP055057908 [Y] 1-24 * the whole document *

DOI: ➔ <http://dx.doi.org/10.1056/NEJM200010123431503>

[Y] - OKAWA ET AL, "Circadian rhythm sleep disorders: Characteristics and entrainment pathology in delayed sleep phase and non-24 sleep-wake syndrome", SLEEP MEDICINE REVIEWS, W.B. SAUNDERS, AMSTERDAM, NL, (20071025), vol. 11, no. 6, doi:10.1016/J.SMRV.2007.08.001, ISSN 1087-0792, pages 485 - 496, XP022341295 [Y] 1-24 * page 488 *

DOI: ➔ <http://dx.doi.org/10.1016/j.smr.2007.08.001>

[Y] - UCHIYAMA M ET AL, "Non-24-Hour Sleep-Wake Syndrome in Sighted and Blind Patients", SLEEP MEDICINE CLINICS, W.B. SAUNDERS CO, US, (20090601), vol. 4, no. 2, doi:10.1016/J.JSMC.2009.02.002, ISSN 1556-407X, pages 195 - 211, XP008161124 [Y] 1-24 * p. 207, 208, chapter "Melatonin Treatment" *

DOI: ➔ <http://dx.doi.org/10.1016/j.jsmc.2009.02.002>

[Y] - RAJARATNAM S M ET AL, "Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials", THE LANCET, LANCET LIMITED, LONDON, GB, vol. 373, no. 9662, doi:10.1016/S0140-6736(08)61812-7, ISSN 0140-6736, (20090207), pages 482 - 491, (20090205), XP025913508 [Y] 1-24 * whole document particularly abstract; Fig. 2c; p. 489, left hand column, second complete paragraph; p. 489, right hand column, second complete paragraph to end of column *

DOI: ➔ [http://dx.doi.org/10.1016/S0140-6736\(08\)61812-7](http://dx.doi.org/10.1016/S0140-6736(08)61812-7)

[Y] - HARDELAND RUEDIGER, "Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders", CURRENT OPINION IN INVESTIGATIONAL DRUGS, THOMSON REUTERS (SCIENTIFIC) LTD, LONDON, UK, (20090701), vol. 10, no. 7, ISSN 2040-3429, pages 691 - 701, XP008161049 [Y] 1-24 * whole document, particularly p. 697, left col., first paragraph of chapter "Current opinion"; p. 698, right col., last paragraph *

[Y] - HARDELAND R, "New approaches in the management of insomnia: Weighing the advantages of prolonged-release melatonin and synthetic melatonineric agonists", NEUROPSYCHIATRIC DISEASE AND TREATMENT, DOVE MEDICAL PRESS (NZ) LTD, NZ, vol. 5, no. 1, ISSN 1176-6328, (20090101), pages 341 - 354, (20090610), XP009137641 [Y] 1-24 * p. 350, first and second paragraph of chapter "Conclusions, place in therapy" *

[XPI] - WALDEMAR OCKERT, "A new dawn in the sleep disorders pipeline?", NATURE REVIEWS DRUG DISCOVERY, (20120720), vol. 11, no. 8, doi:10.1038/nrd3789, ISSN 1474-1776, pages 595 - 596, XP055057972 [XP] 1-4 * table 1 * [I] 5-24

DOI: ➔ <http://dx.doi.org/10.1038/nrd3789>

EPOQUENET

[SS 22] ..fi

Select a database: ..FI EPODOC



Database: EPODOC

Records: 110.949.623

Terms: 1.467.363.440

Occurrences: 22.366.463.607

Last Update: 20181023

[EPODOC: SS 22] BLIND and PATIENTS

Results in EPODOC **383**

[SS 23] MEASURING and CIRCADIAN and RHYTHM

Results in EPODOC **78**

[SS 24] MELATONIN and AGONIST

Results in EPODOC **158**

[SS 25] TASIMELTEON

Results in EPODOC **41**

[SS 26] 22 and 23 and 24 and 25

Results in EPODOC **1**

[SS 27] ..li ti ab pn




1/1 © EPODOC / EPO

TI - TREATMENT OF **CIRCADIAN RHYTHM DISORDERS**

AB - Embodiments of the invention relate to the use of a **melatonin agonist** in the treatment of free running **circadian** rhythms in **patients**, including light perception impaired **patients**, e.g., **blind patients**, and to methods of **measuring circadian rhythm**. In some embodiments, the invention relates to a method of treating a patient suffering from Non-24-Hour Sleep-Wake Disorder that comprises deferring or suspending treatment with **tasimelton** while the patient is being treated with an inducer of CYP3A4.

FIG. 6



PN - [WO2015117048](#) A1 20150806

[SS 27]

ORBIT

Search Step	Result(s)	Query	Assistant	Source	Action
35	2	31 AND 32 AND 33 AND 34	Search history	FAMPAT	Show results Modify Save Alert Delete
34	72	(TASIMELTEON AND (MELATONIN AND AGONIST))/TX/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
33	3210	(CIRCADIAN AND RHYTHM AND DISORDERS)/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
32	1749	(MEASURING AND CIRCADIAN AND RHYTHM)/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
31	7443	(BLIND AND PATIENTS)/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
30	7443	(BLIND AND PATIENTS)/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete

Easy search

Save strategy

MenuFilterExplorer

2 results for 31 AND 32 AND 33 AND 34 - Collection: FAMPAT

PreviewImage

Filter options

1st application year

After 2015 (0)

2011-2015 (2)

2006-2010 (0)

2001-2005 (0)

Before 2001 (0)

Assignee

VANDA PHARMACEUTICALS (2)

Litigations

Oppositions

IPC classification


US classification

Select

Display

#	Title	Publication number	1st app. date	Applicant/Assignee	Litigation
1	Treatment of circadian rhythm disorders	CA2861111	2013-01-25	VANDA PHARMACEUTICALS VANDA PHARMACEUTICALS	

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.



2


Treatment of circadian rhythm disorders

WO2015117048

2015-01-31

VANDA PHARMACEUTICALS*

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. In some embodiments, the invention relates to a method of treating a patient suffering from Non-24-Hour Sleep-Wake Disorder that comprises deferring or suspending treatment with tasimelteon while the patient is being treated with an inducer of CYP3A4.



Treatment of circadian rhythm disorders

FIG. 1

Subjects: 403-1011
Target: Shift: 22:00





FIG. 2



Target Acrophase: 3:00

Visit	Time of Day (h)	Melatonin (ng/h)
Visit S7	12	1000
Visit S7	36	0
Visit S21	12	1000
Visit S21	36	0
Visit S24	12	1000
Visit S24	36	0
Visit S28	12	1000
Visit S28	36	0